Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 10/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.46 |
| ▸ | FEN1 | P39748 | 2/20 | 0.46 |
| ▸ | IDH2 | P48735 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | PARG | Q86W56 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198270 | 1.00 | KMT2A (0.50) | KMT2ATDP1DPP4DPP7KCNH2 | |
| SCHEMBL2193948 | 0.88 | PIK3CD (0.47) | DPP4DPP7KCNH2L3MBTL1DPP8 | |
| SCHEMBL2193946 | 0.88 | PIK3CD (0.47) | DPP4DPP7KCNH2L3MBTL1DPP8 | |
| SCHEMBL2196383 | 0.87 | KMT2A (0.52) | KMT2ATDP1KCNH2ALOX5APFEN1 | |
| SCHEMBL2196387 | 0.87 | KMT2A (0.52) | KMT2ATDP1KCNH2ALOX5APFEN1 | |
| SCHEMBL1723334 | 0.86 | DPP4 (0.56) | DPP4DPP7KCNH2L3MBTL1DPP8 | |
| SCHEMBL2196030 | 0.86 | KMT2A (0.53) | KMT2ATDP1ALOX5APFEN1IDH2 | |
| SCHEMBL16705632 | 0.86 | KMT2A (0.53) | KMT2ATDP1ALOX5APFEN1IDH2 | |
| SCHEMBL2196024 | 0.86 | KMT2A (0.53) | KMT2ATDP1ALOX5APFEN1IDH2 | |
| SCHEMBL2191740 | 0.84 | LMNA (0.55) | KMT2ATDP1ALOX5APFEN1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616037-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2017-04-11 | — | — | US | disclosed |
| US-20160206578-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-9302984-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150266815-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2015-09-24 | — | — | US | disclosed |
| US-9050329-B1 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-20150141472-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| EP-2344449-B1 | ARYL-PHENYL-SULFONAMIDO-CYCLOALKYL COMPOUNDS AND THEIR USE | PIMCO 2664 LTD (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-8822507-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2014-09-02 | — | — | US | disclosed |
| US-20130245018-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (US) | 2013-09-19 | — | — | US | disclosed |
| US-8435968-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| US-20110172189-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172189-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | KMT2A 1816/4885TDP1 3674/4885DPP4 2275/4885 |
| US-20150141472-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | KMT2A 1773/4885TDP1 3764/4885DPP4 2355/4885 |
| US-20130245018-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | KMT2A 1773/4885TDP1 3764/4885DPP4 2355/4885 |
| US-20150266815-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | KMT2A 1773/4885TDP1 3764/4885DPP4 2355/4885 |
| US-20160206578-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | KMT2A 1773/4885TDP1 3764/4885DPP4 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.